Overview

A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

Status:
Completed

Trial end date:
2010-02-01

Target enrollment:

Participant gender:

Summary

Approximately 50 patients undergoing cataract surgery will be randomized in an even allocation (1:1) into two treatment groups, either ketorolac 0.45% BID or bromfenac 0.09% BID. Patients will be instructed to begin dosing study medication in the operative eye the day before surgery and continue dosing until day 14. KOWA flare measurements will be performed at postoperative day one and postoperative day 14. The amount of anterior chamber inflammation (flare) will be objectively measured.

Phase:

Phase 4

Details

Lead Sponsor:

Bucci Laser Vision Institute

Collaborator:

Allergan

Treatments:

Bromfenac
Ketorolac
Ketorolac Tromethamine